EUVIMEDEUVIMED entdecken
Crossref

Development and Preclinical Evaluation of Dual-Target 68Ga/177Lu-Labeled FAP-Bisphosphonate Radioligands with Enhanced Osteoma Retention

Ruiyue Zhao, Yuling Deng, Wenbin Jin, Mingheng Xu, Wanmei Liang, Shaoyu Liu iD, Jiawei Zhong, Jie Lv, Jianxing He, Lin Zhu iD, Xinlu Wang iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01617 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Ruiyue Zhao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong510120, China. Hauptthemen laut MEDLINE: Diphosphonates, Bone Neoplasms, Gallium Radioisotopes, Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangzhou Basic and Applied Basic Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bone metastases and associated skeletal-related events (SREs) severely compromise the survival and quality of life of patients with advanced cancer. Although bisphosphonates enable efficient bone targeting, their radiolabeled analogues exhibit limited uptake in osteolytic lesions due to the low hydroxyapatite content. Fibroblast activation protein, highly expressed in cancer-associated fibroblasts within the tumor microenvironment, provides tumor specificity and may enhance tracer accumulation in osteolytic bone metastases. To overcome this limitation, we developed two heterodimeric [68Ga]Ga/[177Lu]Lu-DOTA-FAPI-bisphosphonate radioligands ([68Ga]Ga/[177Lu]Lu-DFP-1/2) by integrating a FAP-targeting moiety with a bisphosphonate backbone. Both compounds were synthesized with high radiochemical purity (>95%) and excellent in vitro stability. In A549-FAP xenograft models, dynamic PET/CT imaging revealed comparable tumor uptake of [68Ga]Ga-DFP-1/2 and [68Ga]Ga-FAPI-04 up to 2 h postinjection, with [68Ga]Ga-DFP-2 demonstrating faster clearance from nontarget organs. In tibial A549-FAP osteogenic models, [68Ga]Ga-DFP-2 showed significantly higher uptake (4.88 ± 1.01% ID/mL) than mono-FAP or monobisphosphonate tracers (p < 0.05). In osteolytic A549 models, [68Ga]Ga-DFP-2 uptake (3.16 ± 0.82% ID/mL) also exceeded that of monobisphosphonate tracers (p < 0.01). Biodistribution studies confirmed prolonged [177Lu]Lu-DFP-2 retention (26.94 ± 4.40% ID/g at 168 h). Collectively, these findings demonstrate that [68Ga]Ga/[177Lu]Lu-DFP-2 possesses favorable dual bone- and tumor-targeting characteristics and holds strong translational promise as a novel theranostic agent for the imaging and treatment of lung cancer bone metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiphosphonatesBone NeoplasmsGallium RadioisotopesRadioisotopesRadiopharmaceuticalsLutetiumMembrane ProteinsGelatinasesAnimalsHumansMiceFibroblast Activation Protein AlphaCell Line, TumorPositron Emission Tomography Computed TomographyFemaleTissue DistributionXenograft Model Antitumor AssaysEndopeptidasesMice, NudeSerine Endopeptidases

Stichwörter der Autor:innen

Theranosticsbisphosphonatefibroblast activation proteinlung cancer bone metastasis

Substanzen

DiphosphonatesGallium RadioisotopesFibroblast Activation Protein AlphaRadioisotopesRadiopharmaceuticalsLutetiumLutetium-177Membrane ProteinsGelatinasesEndopeptidases

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong510120, China.
  • College of Chemistry, Beijing Normal University, Beijing100875, China.
  • Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University…

ORCID-Profile: Shaoyu Liu, Lin Zhu, Xinlu Wang

Förderung

  • National Natural Science Foundation of China
  • Guangzhou Basic and Applied Basic Research Foundation

Zitieren

APA

Zhao, R., Deng, Y., Jin, W., Xu, M., Liang, W., Liu, S., Zhong, J., Lv, J., He, J., Zhu, L., & Wang, X. (2026). Development and Preclinical Evaluation of Dual-Target 68Ga/177Lu-Labeled FAP-Bisphosphonate Radioligands with Enhanced Osteoma Retention. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01617

Vancouver

Zhao R, Deng Y, Jin W, Xu M, Liang W, Liu S, et al. Development and Preclinical Evaluation of Dual-Target 68Ga/177Lu-Labeled FAP-Bisphosphonate Radioligands with Enhanced Osteoma Retention. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01617

BibTeX
@article{Zhao2026,
  author = {Zhao, Ruiyue and Deng, Yuling and Jin, Wenbin and Xu, Mingheng and Liang, Wanmei and Liu, Shaoyu and Zhong, Jiawei and Lv, Jie and He, Jianxing and Zhu, Lin and Wang, Xinlu},
  title = {Development and Preclinical Evaluation of Dual-Target 68Ga/177Lu-Labeled FAP-Bisphosphonate Radioligands with Enhanced Osteoma Retention},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01617}
}
Kostenlos starten →